Global Schizophrenia Market Drug Forecast and Market Analysis to 2022

"The Report PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2022 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negativeand cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

View Report @ http://www.marketresearchreports.biz/analysis/195924

Highlights

Key Questions Answered

What are the preferred antipsychotic therapies for each country?
The developmental pipeline consists of LAI antipsychotics that address medication compliance concerns. Which of these LAIs will attain high sales revenues during 2012-2022 and in which markets?
Will LAI antipsychotics face adoption challenges in the market? What is the projected uptake of new LAIs, such as Otsuka/Lundbecks Abilify Maintena and Alkermes Aripiprazole lauroxil, over the forecast period?
How large an impact will bitopertin and EVP-6124 have on the schizophrenia market? What do key opinion leaders think of these treatment approaches?
What governmental and industry developments are likely to affect healthcare access and treatment rates in the markets researched? Which is the largest growth market globally?

Get Sample Copy Of This Report @
http://www.marketresearchreports.biz/sample/sample/195924

Key Findings

Country-specific mental health policy heavily influences antipsychotics prescribing patterns and sales in the marketplace.
The impact of negative and cognitive symptom therapies in the marketplace will be challenging without the use of biomarkers and laboratory measurements that can demonstrate a patients response to treatment.
Patient and prescriber endorsements of new and existing LAIs, in particular, atypical LAI antipsychotics, are anticipated to dramatically influence market growth.
Major players will leverage their R&D, manufacturing, and distribution networks to maintain their stakes in the market.

Scope

Overview of schizophrenia, including etiology, general symptoms, and country-specific treatment recommendations and compliance data.
Annualized schizophrenia market revenue, annual cost of vaccination and treatment usage pattern data from 2012 and forecast for ten years to 2022.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the schizophrenia market.
Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically as Otsuka/Lundbecks Abilify Maintena and Alkermes Aripiprazole lauroxil.
Analysis of the current and future market competition in the global schizophrenia drug market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the schizophrenia market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global schizophrenia market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the global schizophrenia market from 2012-2022.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 16
1.2 List of Figures 21

2 Introduction 22
2.1 Catalyst 22
2.2 Upcoming Reports 22

3 Disease Overview 23
3.1 Etiology and Pathophysiology 23
3.1.1 Etiology 23
3.1.2 Pathophysiology 24
3.2 Symptoms 25

4 Epidemiology 26
4.1 Disease Background 26
4.2 Risk Factors and Comorbidities 27
4.2.1 Psychiatric illness in first-degree relatives is a strong predictor of schizophrenia 28
4.2.2 Advancing paternal age increases the risk of schizophrenia in offspring 29
4.2.3 Psychiatric comorbidities are common in patients with schizophrenia 30
4.2.4 People with schizophrenia suffer from several medical comorbidities 31
4.3 Global Trends 34
4.3.1 US 37
4.3.2 5EU 38
4.3.3 Japan 41
4.4 Forecast Methodology 42
4.4.1 Sources Used 42
4.4.2 Sources Not Used 45
4.4.3 Forecast Assumptions and Methods, Prevalent Cases 45
4.5 Epidemiological Forecast of Schizophrenia (2012-2022) 47
4.5.1 Diagnosed Prevalent Cases of Schizophrenia 47
4.5.2 Age-Specific Prevalent Cases of Schizophrenia 49
4.5.3 Sex-Specific Prevalent Cases of Schizophrenia 51
4.5.4 Age-Standardized Diagnosed Prevalence of Schizophrenia 53
4.6 Discussion 54
4.6.1 Epidemiological Forecast Insight 54
4.6.2 Limitations of the Analysis 55
4.6.3 Strengths of the Analysis 56

5 Disease Management 57
5.1 Diagnosis 57
5.1.1 Subjective Assessments 58
5.1.2 Disease Subtypes 59
5.2 Treatment Overview 62
5.2.1 Treatment of Acute Agitation Associated with Schizophrenia 64
5.2.2 Maintenance Treatment of Schizophrenia 65
5.3 US 66
5.3.1 Diagnosis 66
5.3.2 Clinical Practice 66
5.4 France 67
5.4.1 Diagnosis 67
5.4.2 Clinical Practice 68
5.5 Germany 69

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.